Published in Alzheimers Dement on January 30, 2013
Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. Neuroimage Clin (2013) 1.49
Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep (2013) 1.02
Regional white matter hyperintensities: aging, Alzheimer's disease risk, and cognitive function. Neurobiol Aging (2013) 1.00
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement (2015) 0.98
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement (2015) 0.90
Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. JAMA Neurol (2014) 0.87
Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension (2016) 0.87
A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative. Biol Psychiatry (2013) 0.86
Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits. Neurobiol Aging (2014) 0.83
APOE ε4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role? Alzheimers Dement (2014) 0.81
Periventricular hyperintensities are associated with elevated cerebral amyloid. Neurology (2016) 0.81
Cerebral small vessel disease and Alzheimer's disease. Clin Interv Aging (2015) 0.80
Effects of the coexistence of late-life depression and mild cognitive impairment on white matter microstructure. J Neurol Sci (2013) 0.78
Preventing vascular effects on brain injury and cognition late in life: knowns and unknowns. Neuropsychol Rev (2014) 0.77
Cerebral Amyloid and Hypertension are Independently Associated with White Matter Lesions in Elderly. Front Aging Neurosci (2015) 0.76
Entorhinal Cortex Thickness across the Human Lifespan. J Neuroimaging (2015) 0.75
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res (1983) 41.26
Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging (1999) 21.56
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology (2007) 9.27
Cerebral blood flow in dementia. Arch Neurol (1975) 9.24
Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol (2001) 8.88
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol (2009) 4.96
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol (2011) 3.63
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci (2011) 3.23
Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology (2006) 3.22
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology (2005) 2.48
Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatr Psychiatry (2009) 2.46
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging (2004) 2.29
Local histogram correction of MRI spatially dependent image pixel intensity nonuniformity. J Magn Reson Imaging (1996) 2.01
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology (2007) 1.95
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One (2011) 1.79
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 1.70
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging (2010) 1.70
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging (2009) 1.51
Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol (2008) 1.48
Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol (2012) 1.44
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Structural neuroimaging in Altheimer's disease: do white matter hyperintensities matter? Dialogues Clin Neurosci (2009) 1.38
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34
Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clin Ther (2006) 1.19
Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume. Neurobiol Aging (2011) 1.07
CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J Alzheimers Dis (2008) 1.06
CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol Aging (2011) 0.97
Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. Ann N Y Acad Sci (2007) 0.87
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci U S A (2007) 5.30
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage (2010) 4.28
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Physical activity, diet, and risk of Alzheimer disease. JAMA (2009) 4.11
Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage (2007) 4.07
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage (2011) 3.47
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage (2009) 3.13
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology (2009) 2.90
Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement (2010) 2.88
Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One (2009) 2.85
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology (2009) 2.70
Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry (2009) 2.70
Voxelwise genome-wide association study (vGWAS). Neuroimage (2010) 2.69
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol (2010) 2.61
Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain (2009) 2.61
Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain (2009) 2.51
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates. Neuroimage (2011) 2.50
Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. Neuroimage (2009) 2.47
Mediterranean diet and magnetic resonance imaging-assessed cerebrovascular disease. Ann Neurol (2011) 2.44
Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med (2009) 2.43
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 2.37
Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage (2010) 2.32
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiol Aging (2008) 2.31
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.30
Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain (2008) 2.28
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp (2009) 2.28
Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage (2010) 2.27
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.25
Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp (2009) 2.24
Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage (2009) 2.22
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology (2009) 2.18
CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci (2010) 2.18
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging (2010) 2.13
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A (2010) 2.12
Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage (2012) 2.11
LEAP: learning embeddings for atlas propagation. Neuroimage (2009) 2.09
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology (2011) 2.08
Validity of self-reported stroke in elderly African Americans, Caribbean Hispanics, and Whites. Arch Neurol (2009) 2.05
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology (2014) 2.03
Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. Alzheimer Dis Assoc Disord (2012) 2.02
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage (2009) 1.95
Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry (2011) 1.94
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol (2010) 1.94
Mechanisms of association between obesity and chronic pain in the elderly. Pain (2011) 1.94
Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. Neuroimage (2010) 1.94
The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol (2008) 1.92
Genome-wide association study of Alzheimer's disease. Transl Psychiatry (2012) 1.88
Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters. Neuroimage (2010) 1.87
Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology (2010) 1.86
Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol (2009) 1.86
Ensemble sparse classification of Alzheimer's disease. Neuroimage (2012) 1.84
Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal (2011) 1.82
The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol (2011) 1.79
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One (2011) 1.79
Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage (2012) 1.76
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol (2011) 1.75
Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology (2013) 1.75
Magnetic resonance imaging analysis of amygdala and other subcortical brain regions in adolescents with bipolar disorder. Bipolar Disord (2004) 1.73
Abnormal cortical networks in mild cognitive impairment and Alzheimer's disease. PLoS Comput Biol (2010) 1.72
BEaST: brain extraction based on nonlocal segmentation technique. Neuroimage (2011) 1.72
Regional shape abnormalities in mild cognitive impairment and Alzheimer's disease. Neuroimage (2009) 1.71